← Back to Search

Moisturizer Routine Monitoring for Eczema

N/A
Waitlist Available
Led By Steven R Feldman, MD, PhD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is 18 years of age or older.
Subject with a diagnosis of xerosis in the context (current or historic) of atopic dermatitis
Must not have
Subjects under 18 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 3 month
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether measuring a person's skin hydration levels will help them to better follow their moisturizer routine and prevent disease relapse.

Who is the study for?
This trial is for adults over 18 with dry skin (xerosis) related to eczema or atopic dermatitis, who can communicate in English. It's not suitable for those under 18 or without a working knowledge of English.
What is being tested?
The study tests if monitoring skin hydration and water loss helps people stick to using Cetaphil Pro Eczema moisturizer daily. Participants will either get no extra help, answer weekly surveys, or use a device (GPSkin) that checks how well the moisturizer works.
What are the potential side effects?
Since this trial involves the use of a topical moisturizer and electronic devices for monitoring, side effects are minimal but may include mild skin irritation from the product or discomfort from using the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have dry skin due to current or past eczema.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 3 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 3 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adherence - Moisturizer
Transepidermal water loss (TEWL) rates
Xerosis Severity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: GPSkin groupExperimental Treatment2 Interventions
The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
Group II: Digital Interaction GroupExperimental Treatment2 Interventions
The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
Group III: Control GroupExperimental Treatment1 Intervention
All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,397 Previous Clinical Trials
2,460,094 Total Patients Enrolled
7 Trials studying Eczema
646 Patients Enrolled for Eczema
Galderma R&DIndustry Sponsor
302 Previous Clinical Trials
60,633 Total Patients Enrolled
13 Trials studying Eczema
4,203 Patients Enrolled for Eczema
Steven R Feldman, MD, PhDPrincipal InvestigatorWake Forest University Health Sciences
14 Previous Clinical Trials
568 Total Patients Enrolled
3 Trials studying Eczema
40 Patients Enrolled for Eczema

Media Library

Use of Topical Moisturizer Clinical Trial Eligibility Overview. Trial Name: NCT04341623 — N/A
Eczema Research Study Groups: Digital Interaction Group, GPSkin group, Control Group
Eczema Clinical Trial 2023: Use of Topical Moisturizer Highlights & Side Effects. Trial Name: NCT04341623 — N/A
Use of Topical Moisturizer 2023 Treatment Timeline for Medical Study. Trial Name: NCT04341623 — N/A
~1 spots leftby Feb 2025